Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Growth Hormone-Releasing Hormone Receptor (GHRHR) Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GHRHR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GHRHR ECD-Fc Fusion Protein High purity (>95%), HEK293 expressed. Sequence Verified. |
View GHRHR Products |
| Gene Delivery | GHRHR Lentivirus Premade Particles Full-length ORF for stable cell line construction. Preserves native 7-TM topology. |
View GHRHR Products |
| Benchmark Ab | Anti-GHRHR Control Antibody Recombinant positive control for binding and flow cytometry. Sequence Verified. |
View GHRHR Products |
| Validator | GHRHR siRNA Set For knockdown verification and specificity checks. |
View GHRHR Products |
| Ligand Control | GHRH (Growth Hormone Releasing Hormone) Native ligand for competition and activation assays. |
View GHRH Products |
| Pathway Antagonist | SSTR2 (Somatostatin Receptor 2) Counter-regulatory pathway target for combination studies. |
View SSTR2 Products |
| Related Target | IGF1 (Insulin-like Growth Factor 1) Downstream signaling biomarker for pharmacodynamics. |
View IGF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity | Full-length Lentivirus delivery preserving native glycosylation and 7-TM topology; ensures native folding for functional assays. |
| Cross-species Translation (Human/Mouse/Cyno) | Human/Mouse/Cyno ortholog proteins available with >95% purity, Endotoxin <1EU/µg; sequence-verified cross-reactivity testing. |
| Class B Subfamily Selectivity | Strictly purified ECD domains verified by Mass Spec to exclude VIPR/PAC1R cross-reactivity; homolog counter-screens available. |
| Assay Controls & Specificity | Clinical Benchmark Antibodies and sequence-verified siRNA included for precise standardization and false positive reduction. |
Live GHRHR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The GHRHR therapeutic landscape is bifurcated between agonist strategies for growth hormone deficiency (GHD) and antagonist approaches for oncological indications. While peptide-based GHRH analogs (e.g., Tesamorelin) dominate the current market for HIV-associated lipodystrophy and GHD, the next wave focuses on small molecule and antibody-based GHRHR antagonists to block growth hormone release in sensitive tumors. Major players such as Theratechnologies, Novo Nordisk, Pfizer, and Ascendis are diversifying into orally bioavailable small molecules and long-acting depot formulations. Research is expanding into prostate, lung, breast, and pancreatic cancers driven by aberrant GHRHR signaling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Agonist | Ipsen, Theratechnologies, Novo Nordisk | GHD, HIV Lipodystrophy | Receptor Binding & Activation (Need high-purity GHRH ligand and stable cell lines) |
| Peptide Antagonist | Various Academic/Biotech | Prostate/Lung Cancer, Acromegaly | Inhibition Assays (Need high-expression cell models) |
| Small Molecule (Antagonist) | Pfizer, Ascendis, Various Biotech | Prostate, Breast, Pancreatic Cancer; Metabolic Disorders | Allosteric Site Screening & Selectivity (Need stable GHRHR membrane prep and homolog counter-screens) |
| Biologic Antagonist | Early Phase | Solid Tumors | Internalization Assay (Need full-length cell line for ADC/PDC evaluation) |